Skip to main content

Table 1 Summary of the main characteristics of the included studies

From: Prognostic and clinicopathologic significance of circZFR in multiple human cancers

Author Year Country Cancer type Clinical stage Sample size Cut-off value Follow-up (months) Detection method Adjuvant therapy Survival analysis Outcome measure NOS
Cedric, B [15] 2020 China HCC T1–T4 62 Mean qRT–PCR None Univariate CP 7
Chen, Z [19] 2020 China BrC I–IV 70 Median 60 qRT–PCR N/A Univariate OS, CP 9
Fang, N [23] 2020 China ESCC I–IV 58 Median qRT–PCR None Univariate CP 7
Huang, S [21] 2020 China GC 60 N/A 60 qRT–PCR None Univariate OS 8
Huang, W [24] 2020 China BlC 55 Median 60 qRT–PCR None Univariate OS, DFS 8
Li, L [25] 2021 China HCC I–III 49 N/A qRT–PCR None Univariate CP 7
Lin, Y [26] 2021 China HCC I–IV 50 Median 60 qRT–PCR None Multivariate OS,CP 9
Liu, M [20] 2020 China BrC I–IV 65 Median 54 qRT–PCR None Univariate OS, CP 8
Liu, W [16] 2018 China LC 44 N/A 80 qRT–PCR None Univariate OS 8
Luo, L [27] 2021 China BlC I–IV 60 N/A 78 qRT–PCR N/A Univariate OS,CP 8
Tan, A [28] 2019 China HCC 80 Mean 60 qRT–PCR None Univariate OS 8
Wei, H [17] 2018 China PTC 41 N/A 60 qRT–PCR N/A Univariate OS 8
Xu, R [29] 2021 China HCC I–IV 40 N/A qRT–PCR None Univariate CP 7
Yang, X [30] 2019 China HCC I–IV 30 Median qRT–PCR None Univariate CP 7
Zhang, P [22] 2017 China CRC I–IV 170 N/A qRT–PCR None Univariate CP 7
Zhang, W [18] 2019 China BlC Ta–T4 104 Median 72 qRT–PCR None Univariate OS, PFS, CP 9
Zhan, W [31] 2020 China HCC I–IV 60 N/A 100 qRT–PCR None Univariate OS, CP 9
  1. Abbreviations: BlC bladder cancer, BrC breast cancer, CRC colorectal cancer, CP clinicopathological parameters, DFS disease-free survival, ESCC esophageal squamous cell cancer, GC gastric cancer, HCC hepatocellular carcinoma, LC lung cancer, N/A not available, NOS Newcastle-Ottawa Scale, OS overall survival, PFS progression-free survival, PTC papillary thyroid cancer, qRT-PCR quantitative real-time polymerase chain reaction